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Tc-methylene diphosphonate (MDP) bone scan has been the standard method for nuclear medicine imaging of the skeleton for decades, providing information about the presence, extent, location, and response to treatment in patients with osseous metastasis. For better resolution and characterization, up to 20 mCi or more of tracer is required and still higher doses are required for obese population, leading to higher radiation burden and secondary increased risk of cancer.
[1] Currently, bone imaging is a part of oncology workup as a pretreatment staging; however, an interim and end-of-therapy scan is also advised for response evaluation in metastatic bone disease, leading to a cumulative absorbed doses of approximately 18-19 mSv for a given line of treatment.
It is well known that cancer risk is induced from radiation.
[1,2] Lifetime attributable risk of cancer incidence, according to the principles of the National Academies' Biological Effects of Ionizing Radiation Report VII, was calculated to be between 0.231% and 0.514% for 20-year-old females and between 0.163% and 0.323% for 20-year-old males. [3] Rediscovered 18 F-sodium fluoride (NaF) positron emission tomography-computed tomography (PET-CT) has revolutionized the bone imaging in the recent past and has shown to be a promising agent for the management of bone disorders. [4] Distinguished properties of this tracer include rapid clearance from plasma in a biexponential manner, with most of the tracer retained by the bone after a single pass (chemisorption with the exchange of Tc-based tracers (2-3 h). [4, 5] Segall et al. suggested a fixed-dose method of imaging dose of 18 F-NaF, that is, 185-370 MBq (5-10 mCi) in 2010 in procedure guideline of SNMMI. [6] The fixed-dose method varied from physician to physician, leading to a lack of standardized formula for NaF imaging till date. The effective absorbed doses by this fixed method came out to be even higher than the Tc-MDP. [9] Further refinement of the idea was done by Lim et al. who reported that the radiation dosimetry for 18 F-NaF PET is similar to that with 99m Tc-MDP imaging, and good-quality 18 F-NaF imaging can be effectively performed using a smaller administered dosage than is typically employed for MDP, resulting in an actual radiation absorbed dose that is equivalent to that received from standard single-photon imaging. [10] Chilton et al. [11] reported that the total uptake of 18 F-fluoride by the bone is similar to that of 99m Tc-MDP, at approximately 50% of the injected dose. [11] Considering the imaging point of view, the soft-tissue half-value layers for the 511-and 140-keV photons are 7.3 and 4.6 cm, respectively; it means that 511-keV photons can deliver their energy to organs distant from the source organ, making imaging better, whereas the 140-keV photons will deliver more of their energy to organs near the source organ.
Keeping in view the inference of Ohnona et al., Lim et al., and Chilton et al., we performed prospective 18 F-NaF imaging in 6000 patients from January 2012 to December 2016. 1062/6000 were included in evaluation of low-dose NaF study standardizing the imaging dose as 0.06 mCi/ kg [7] followed by a prospective study of 212/6000 morbidly obese patients for evaluation of the effect of body mass index (BMI) in 18 F-NaF imaging. [12] Prospective imaging data of a large cohort of 1062 patients by Marafi et al. [7] showed significant dose reduction keeping the imaging quality at acceptable levels, which is in accordance with the already published results of Ohnona et al. Good-quality 18 F-NaF imaging was seen at the lowest dose standards of 0.06 mCi/kg for all age groups excluding the pediatric population [ Figure 1 ]. Similarly, by following KCCC protocols, the dose exposure is 12% and 14 % lower than the EANM recommended injected dose range of minimum and maximum, respectively i.e. (1.5-3.7 MBq/kg). [8] This work is also supported by SKELETA clinical trial conducted by Jambor et al. who report that 18 F-NaF PET-CT is more sensitive, accurate, and has less equivocal findings than Tc-HDP SPECT-CT for the detection of bone metastases in high-risk breast and prostate cancer patients. [13] Conclusion/Suggestions 18 F-NaF, a lost and found molecule, has time-proven potential for evaluation of bone diseases. In the light of the above data, we infer that through proper tailoring of injected doses of NaF, high-quality imaging can be achieved keeping the injected doses at minimum levels. [7] Minimum-maximum [8] KCCC: Kuwait Cancer Control Center, Kuwait, SNMMI: Society of Nuclear Medicine and Molecular Imaging, [6] EANM: European Society of Nuclear Medicine and Molecular Imaging [8] Here, we suggest a new standard for adult bone imaging dose of 0.06 mCi/kg for 18 F-NaF based on the recently published data. Keeping in view the potential of 18 F-NaF, due to its unique in vivo chemistry, we suggest to update the current available guidelines of 18 F-NaF adult bone imaging in nuclear medicine.
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